Clinical Trial Detail

NCT ID	NCT03037385
Title	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Blueprint Medicines Corporation
Indications	Advanced Solid Tumor thyroid gland medullary carcinoma lung non-small cell carcinoma
Therapies	Pralsetinib
Age Groups:	adult senior